Shanghai, China

Xinhui Xiong

This inventor holds 1 USPTO granted patent. Top assignee: Mabwell (Shanghai) Bioscience Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xinhui Xiong. Retrieved from https://idiyas.com/inventor/xinhui-xiong

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Xinhui Xiong

Introduction

Xinhui Xiong is a notable inventor based in Shanghai, China. He has made significant contributions to the field of bioscience, particularly through his innovative patent work. His expertise and dedication to research have positioned him as a key figure in his industry.

Latest Patents

Xinhui Xiong holds a patent for the "ANTI-ST2 ANTIBODY, ENCODING NUCLEIC ACID MOLECULES THEREOF AND METHODS OF USE THEREOF." This patent reflects his commitment to advancing medical science and improving therapeutic options.

Career Highlights

Xinhui Xiong is currently employed at Mabwell (Shanghai) Bioscience Co., Ltd. His role at the company allows him to engage in cutting-edge research and development, contributing to the advancement of bioscience technologies.

Collaborations

Xinhui collaborates with talented individuals in his field, including coworkers Xing Li and Hong Pan. Their combined expertise fosters a productive environment for innovation and discovery.

Conclusion

Xinhui Xiong's contributions to bioscience through his patent and collaborative efforts highlight his importance as an inventor. His work continues to influence the field and pave the way for future advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…